AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01020760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face down posture
Description: Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
Study NCT06241586 — intervention group
Intervention type: PROCEDURE
Intervention: The novel PMMI surgical strategy
Description: Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals.
Study NCT04264832 — intervention group
Intervention type: OTHER
Intervention: Clinical data collection
Description: Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life .
Study NCT01342237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDCT 1(TTC), HDCT2(MEC)
Description: 1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)
Study NCT04109508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
Study NCT04592718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow deep breathing plus breath counting
Description: Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
Study NCT04592718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal-paced breathing plus breath counting
Description: Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
Study NCT01561196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arterial catheterisation
Description: arterial catheterisation in Arterial Radialis
Study NCT03084380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
Description: transcatheter arterial chemoembolization + CAR-T infusion
Study NCT03084380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at dose of 25mg/m2/d
Study NCT03084380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
Study NCT03769610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Foley catheter
Study NCT03769610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Foley catheter
Study NCT01816945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMBA web-based application
Description: Web-based, interactive, social network application.
Study NCT06241586 — intervention group
Intervention type: PROCEDURE
Intervention: The conventional step-up strategy
Description: Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
Study NCT01984255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV
Description: Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
Study NCT01984255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
Description: Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
Study NCT03734757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: imaging in trimodality
Description: PET-CT and MRI
Study NCT04799041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTX 2/3
Description: There were 15 patients in this group. Each one received only one treatment.
Study NCT04799041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There were 15 patients in this group. Each one received only one treatment.
Study NCT01641120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Intramuscular injection administered using 25 gauge or 30 gauge needle
Study NCT03782454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood samples taken every third hour during the first 48 hours of intensive care
Study NCT04378283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)
Description: The study is designed to evaluate topical anesthetics
Study NCT04378283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA plus infiltration as anesthetic for wound repair.
Description: EMLA plus infiltration as anesthetic for wound repair.
Study NCT02132104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine application of amnion membrane
Description: Uterine application of amnion membrane following hysteroscopic adhesiolysis.
Study NCT02132104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley balloon
Description: Uterine application of Foley balloon
Study NCT02132104 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Foley balloon
Description: Uterine application of Foley balloon
Study NCT02132104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston
Description: Hormones treatment after surgery.
Study NCT02132104 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Femoston
Description: Hormones treatment after surgery.
Study NCT01178138 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prazosin
Description: Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
Study NCT02514967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Description: Administered via subcutaneous injection once per week
Study NCT02514967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection once per week
Study NCT00565994 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
Study NCT03695913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Phase I (regular diet):~all participants will eat their normal diet and will log their food.
Study NCT03695913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carb diet
Description: Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food
Study NCT03695913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM with no real time feedback
Description: Phase I will collect CGM without real time feedback
Study NCT03695913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM with real time feedback)
Description: Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.
Study NCT03695913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education material
Description: Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make.
Study NCT03980366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
Study NCT03729778 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar-13
Description: One time administration of prevnar-13 vaccine
Study NCT03144648 — intervention group
Intervention type: OTHER
Intervention: lifestyle
Description: Observational study
Study NCT01601899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 30 mg po BD if wt \< 60kg, or 40 mg po BD if wt > 60kg
Study NCT01601899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 20 mg po BD if wt \< 60kg, or 30 mg po BD if wt > 60kg
Study NCT01601899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: 300 mg po QD
Study NCT01909284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: * BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~* Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture.
Study NCT01909284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural nerve block
Description: Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
Study NCT01909284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural nerve block
Description: Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
Study NCT00845195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl Nasal Spray, 0.6%
Description: 2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
Study NCT00845195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine HCl Nasal Spray, 0.1%
Description: 2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
Study NCT03575026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-with-movement
Description: Subjects will listen their preferred music and move their body actively with music
Study NCT03575026 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Social activity acts as control with similar dose and intensity with intervention arm
Study NCT01158339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 2: CBGT-ISE
Description: Intervention with active performance of the feared movements during group sessions.
Study NCT01158339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: CBGT
Description: Intervention according to previously mentioned methods.
Study NCT02569060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing and Monitoring of Blood Glucose Levels
Description: Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
Study NCT02569060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing and Monitoring of Blood Glucose Levels
Description: Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
Study NCT02569060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care coordination
Description: Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
Study NCT02569060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care coordination
Description: Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
Study NCT02569060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-appropriate food packages
Description: Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
Study NCT02569060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes-appropriate food packages
Description: Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
Study NCT02569060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education
Description: Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
Study NCT02569060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes self-management education
Description: Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
Study NCT03903380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Usual care exercise protocol for neck pain
Description: Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
Study NCT00852514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance-guide dry weight reduction
Description: for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
Study NCT02036151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylitol
Description: Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
Study NCT02036151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish application
Description: The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
Study NCT02825797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117
Study NCT02825797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 10-1074
Study NCT03903380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Augmented reality exercise protocol
Description: Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
Study NCT04835012 — intervention group
Intervention type: OTHER
Intervention: Medical debt forgiveness
Description: A non-profit charity, RIP Medical Debt, bought and retired medical debt for individuals that were assigned to the treatment group.
Study NCT01120665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate
Description: estradiol valerate, 1 mg/day, orally.
Study NCT02825797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption
Description: Analytical treatment interruption
Study NCT02825797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of placebo (sterile saline)
Study NCT01120665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
Study NCT01120665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
Study NCT01120665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
Study NCT02894840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: an inactivated influenza vaccine
Description: The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
Study NCT02894840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
Study NCT01652287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB-12 supplemented strawberry yogurt
Description: Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
Study NCT01652287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry flavored yogurt
Description: Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
Study NCT02000804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib 160mg
Description: drug
Study NCT04360356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ivermectin plus Nitazoxanide
Description: Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
Study NCT04360356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Oxygen via Ventilators
Study NCT01523847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBVD (Myocet+BVD)
Description: MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15
Study NCT06119750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NS Solution
Description: This will be administered via skin patch.
Study NCT02473536 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiation therapy
Description: SABR
Study NCT04382664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 vaccine (300 μg) will be injected intradermally.
Study NCT04382664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim (75 μg) is used as a vaccine adjuvant.
Study NCT04382664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab is dosed according to label.
Study NCT04382664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is dosed according to label.